JP2017512304A - バイオマーカーシグネチャー法ならびにそのための装置およびキット - Google Patents

バイオマーカーシグネチャー法ならびにそのための装置およびキット Download PDF

Info

Publication number
JP2017512304A
JP2017512304A JP2016550561A JP2016550561A JP2017512304A JP 2017512304 A JP2017512304 A JP 2017512304A JP 2016550561 A JP2016550561 A JP 2016550561A JP 2016550561 A JP2016550561 A JP 2016550561A JP 2017512304 A JP2017512304 A JP 2017512304A
Authority
JP
Japan
Prior art keywords
biomarker
immune system
gene
irs
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512304A5 (https=
Inventor
リチャード、ブルース、ブランドン
レオ、チャールズ、マクヒュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunexpress Pty Ltd
Original Assignee
Immunexpress Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900363A external-priority patent/AU2014900363A0/en
Application filed by Immunexpress Pty Ltd filed Critical Immunexpress Pty Ltd
Publication of JP2017512304A publication Critical patent/JP2017512304A/ja
Publication of JP2017512304A5 publication Critical patent/JP2017512304A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Artificial Intelligence (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
JP2016550561A 2014-02-06 2015-02-06 バイオマーカーシグネチャー法ならびにそのための装置およびキット Pending JP2017512304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014900363A AU2014900363A0 (en) 2014-02-06 Biomarker Signature Method, and Apparatus and Kits Therefor
AU2014900363 2014-02-06
PCT/AU2015/050043 WO2015117204A1 (en) 2014-02-06 2015-02-06 Biomarker signature method, and apparatus and kits therefor

Publications (2)

Publication Number Publication Date
JP2017512304A true JP2017512304A (ja) 2017-05-18
JP2017512304A5 JP2017512304A5 (https=) 2018-04-19

Family

ID=53754326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550561A Pending JP2017512304A (ja) 2014-02-06 2015-02-06 バイオマーカーシグネチャー法ならびにそのための装置およびキット

Country Status (8)

Country Link
US (4) US11047010B2 (https=)
EP (1) EP3103046B1 (https=)
JP (1) JP2017512304A (https=)
CN (1) CN105981026A (https=)
AU (1) AU2015213486B2 (https=)
CA (1) CA2930925A1 (https=)
DK (1) DK3103046T3 (https=)
WO (1) WO2015117204A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111052247A (zh) * 2017-06-13 2020-04-21 波士顿基因公司 用于由经归一化生物标志物评分鉴定癌症治疗的系统和方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
CN108513586A (zh) * 2015-09-30 2018-09-07 因姆内克斯普雷斯私人有限公司 病原体生物标志物及其用途
EP3371324B1 (en) * 2015-11-06 2021-08-18 ImmuneXpress Pty Ltd Viral biomarkers and uses therefor
CN106701900B (zh) * 2015-11-16 2020-03-20 上海市东方医院 长链非编码rna herc2p3基因及其在胃癌中的用途
CN105256063B (zh) * 2015-12-01 2019-03-01 北京泱深生物信息技术有限公司 肿瘤标志物dmbx1及其应用
AU2016377391B2 (en) 2015-12-24 2022-09-01 Immunexpress Pty Ltd Triage biomarkers and uses therefor
CN105506172B (zh) * 2016-03-01 2019-04-09 北京泱深生物信息技术有限公司 含检测gfod2的骨质疏松血液诊断试剂及其应用
US20230187067A1 (en) * 2016-03-23 2023-06-15 Peach Intellihealth, Inc. Use of clinical parameters for the prediction of sirs
AU2017315328A1 (en) * 2016-08-24 2019-03-21 Immunexpress Pty Ltd Systemic inflammatory and pathogen biomarkers and uses therefor
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
JP7274748B2 (ja) 2016-11-08 2023-05-17 クヴェッラ コーポレーション 核酸の安定化及び分離を行う方法
CN106755343A (zh) * 2016-12-01 2017-05-31 北京致成生物医学科技有限公司 胰腺癌预后诊断分子标记物
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
WO2018140256A1 (en) * 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
CN108341862B (zh) * 2017-01-24 2021-04-02 上海交通大学医学院附属仁济医院 一种多肽及其应用
CN106947808B (zh) * 2017-03-10 2020-07-24 北京赛尔得生物技术有限公司 Tmem104基因在制备治疗椎间盘退行性疾病药物中的应用
CN107133475B (zh) * 2017-05-10 2020-09-29 浙江省立同德医院 一种中药注射剂不良反应高危患者模式识别方法
WO2019095064A1 (en) * 2017-11-15 2019-05-23 UNIVERSITé LAVAL Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
CN108467890A (zh) * 2018-05-02 2018-08-31 首都医科大学附属北京天坛医院 Vat1基因及vat1基因的干扰物的应用和应用vat1基因的产品
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
WO2020096984A1 (en) * 2018-11-05 2020-05-14 Institute For Systems Biology Sepsis biomarker panels and methods of use
AU2019380342A1 (en) * 2018-11-15 2021-07-01 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization
WO2020132327A1 (en) * 2018-12-19 2020-06-25 The Trustees Of The University Of Pennsylvania Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
CN111443065A (zh) * 2019-01-17 2020-07-24 四川大学华西医院 一种肺癌的筛查试剂盒
CN109762911B (zh) * 2019-02-21 2020-12-01 华中农业大学 Ptprj基因作为猪免疫相关性状的分子标记及其应用
US12288623B2 (en) 2019-03-19 2025-04-29 Optina Diagnostics, Inc. Method and system for identifying subjects who are potentially impacted by a medical condition
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
CN110558279B (zh) * 2019-09-16 2021-11-16 南方科技大学 一种药物筛选模型、药物筛选方法及其应用
CN110687285B (zh) * 2019-10-29 2023-03-21 安徽医科大学 诊断试剂盒及mak16在制备系统性红斑狼疮早期诊断试剂中的应用
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
CN111276248B (zh) * 2020-01-20 2023-09-12 苏州帕诺米克生物医药科技有限公司 状态确定系统和电子设备
CN114317746B (zh) * 2020-03-30 2022-09-23 中国医学科学院肿瘤医院 外泌体arpc5、ypel2等在肺癌诊断中的应用
CA3178405A1 (en) 2020-05-14 2021-11-18 Katherine A. OWEN Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
CN114487402A (zh) * 2020-11-12 2022-05-13 首都医科大学附属北京世纪坛医院 尿液非分泌核糖核酸酶蛋白及其多肽片段在妊娠糖尿病中的应用
CN112553322B (zh) * 2020-12-25 2022-07-05 深圳市人民医院 一种骨质疏松诊断标志物及其应用
CA3211700A1 (en) * 2021-02-11 2022-08-18 Herbert A. Fritsche Kits and methods for detecting markers and determining the presence or risk of cancer
CN113125757B (zh) * 2021-04-22 2022-10-28 石河子大学 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法
WO2022226267A1 (en) * 2021-04-23 2022-10-27 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN
AU2022283025A1 (en) * 2021-05-25 2024-01-18 The University Of British Columbia Diagnostic for sepsis endotypes and/or severity
WO2023034111A1 (en) * 2021-08-30 2023-03-09 Inflammatix, Inc. A baseline gene expression-based prognostic for anti-tnf alpha therapy response in patients with inflammatory bowel disease
AU2022375208B2 (en) * 2021-10-29 2024-06-06 GenoDx Pty Ltd Biomarkers and uses therefor
CN114875144B (zh) * 2022-04-02 2026-04-17 及智(苏州)医学技术有限公司 用于评估肿瘤ibc疗法的疗效的生物标志物、系统、方法及试剂盒
WO2023224913A1 (en) * 2022-05-16 2023-11-23 Cz Biohub Sf, Llc Integrated host-microbe metagenomics of cell-free nucleic acid for sepsis diagnosis
EP4471784A1 (fr) * 2023-05-31 2024-12-04 Biomérieux Procede et systeme de typage probabiliste de souches microbiennes
EP4471785A1 (fr) * 2023-05-31 2024-12-04 Biomérieux Procede et systeme de typage probabiliste de souches microbiennes
WO2025257393A1 (en) * 2024-06-14 2025-12-18 Roche Diagnostics Gmbh Method and system for improving biomarker based disease assessments
CN119842884B (zh) * 2025-01-09 2025-09-19 湖北文理学院 Tm9sf1在制备用于监测脓毒症病程的试剂中的应用
CN120405150B (zh) * 2025-07-01 2025-11-18 南昌大学第一附属医院 Itga6在制备脓毒症诊断及病情监测试剂或试剂盒中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
JP2006506070A (ja) * 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを用いた敗血症またはｓｉｒｓの診断
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
WO2009045443A2 (en) * 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
JP2009229340A (ja) * 2008-03-25 2009-10-08 Sysmex Corp 全身性炎症反応症候群の重症度に関する情報を生成する方法及び装置
JP2010537659A (ja) * 2007-09-07 2010-12-09 ユニヴェルシテ リブル ドゥ ブリュッセル Ｅｒ−患者におけるガンの予後判定のための方法およびツール
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980488A7 (fi) * 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20070134261A1 (en) 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US20040096917A1 (en) 2002-11-12 2004-05-20 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
US20080070235A1 (en) 2003-04-02 2008-03-20 Sirs-Lab Gmbh Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
DE102004009952B4 (de) 2004-03-01 2011-06-01 Sirs-Lab Gmbh Verfahren zur Erkennung von Sepsis
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
DE102005050933A1 (de) 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20090297474A1 (en) * 2005-11-25 2009-12-03 Dermot Kelleher Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
DE102008000715B9 (de) 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
CA2749601C (en) * 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
US20110076685A1 (en) 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110312521A1 (en) 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
US20140037649A1 (en) 2010-11-26 2014-02-06 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
EP2756118A4 (en) 2011-09-16 2015-09-16 Cepheid METHOD FOR DETECTING SEPSIS
US20150315643A1 (en) 2012-12-13 2015-11-05 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
JP2006506070A (ja) * 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを用いた敗血症またはｓｉｒｓの診断
JP2006506069A (ja) * 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを用いた敗血症またはｓｉｒｓの診断
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
JP2010537659A (ja) * 2007-09-07 2010-12-09 ユニヴェルシテ リブル ドゥ ブリュッセル Ｅｒ−患者におけるガンの予後判定のための方法およびツール
WO2009045443A2 (en) * 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009229340A (ja) * 2008-03-25 2009-10-08 Sysmex Corp 全身性炎症反応症候群の重症度に関する情報を生成する方法及び装置

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111052247A (zh) * 2017-06-13 2020-04-21 波士顿基因公司 用于由经归一化生物标志物评分鉴定癌症治疗的系统和方法
JP2020523705A (ja) * 2017-06-13 2020-08-06 ボストンジーン コーポレイションＢｏｓｔｏｎＧｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
JP2021036868A (ja) * 2017-06-13 2021-03-11 ボストンジーン コーポレイションＢｏｓｔｏｎＧｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
US11004542B2 (en) 2017-06-13 2021-05-11 Bostongene Corporation Using subject sequencing data and a database of therapy biomarker distributions to determine therapy impact
JP6999771B2 (ja) 2017-06-13 2022-02-04 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
JP2022050445A (ja) * 2017-06-13 2022-03-30 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
US11705220B2 (en) 2017-06-13 2023-07-18 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
JP7343565B2 (ja) 2017-06-13 2023-09-12 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
JP2023169202A (ja) * 2017-06-13 2023-11-29 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
US11842797B2 (en) 2017-06-13 2023-12-12 Bostongene Corporation Systems and methods for predicting therapy efficacy from normalized biomarker scores
JP7401710B2 (ja) 2017-06-13 2023-12-19 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法

Also Published As

Publication number Publication date
AU2015213486A1 (en) 2016-06-02
EP3103046A4 (en) 2017-08-23
EP3103046B1 (en) 2020-03-25
CA2930925A1 (en) 2015-08-13
AU2015213486B2 (en) 2020-10-22
US20220325348A1 (en) 2022-10-13
US20150259746A1 (en) 2015-09-17
US11047010B2 (en) 2021-06-29
WO2015117204A1 (en) 2015-08-13
WO2015117204A9 (en) 2016-06-23
EP3103046A1 (en) 2016-12-14
AU2015213486A9 (en) 2016-07-07
US20170191129A1 (en) 2017-07-06
CN105981026A (zh) 2016-09-28
US20150218640A1 (en) 2015-08-06
DK3103046T3 (da) 2020-06-02
US10865447B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
US20220325348A1 (en) Biomarker signature method, and apparatus and kits therefor
US20260015666A1 (en) Biomarker identification
US20240201186A1 (en) Triage biomarkers and use therefor
KR20170053617A (ko) 폐암 상태를 평가하는 방법
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
CN118207336B (zh) 一种诊断和评估肺结节癌症风险的血液基因表达生物标志物组
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
WO2015117205A1 (en) Biomarker signature method, and apparatus and kits therefor
HK1228037A1 (en) Biomarker signature method, and apparatus and kits therefor
WO2026036182A1 (en) Biomarkers and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200602